



Review

Diagnosis and classification of sporadic inclusion body myositis (sIBM)

M. Catalán^a, A. Selva-O'Callaghan^b, J.M. Grau^{a,c,*}^a Fundació Privada Cellex, University of Barcelona, Spain^b Internal Medicine Service, Hospital Vall d'Hebrón, Barcelona, Spain^c Internal Medicine Service, Hospital Clínic of Barcelona, University of Barcelona, Spain

ARTICLE INFO

Article history:

Accepted 13 November 2013

Available online 12 January 2014

Keywords:

Inclusion body

Myositis

Myopathy

Inflammation

ABSTRACT

Sporadic inclusion body myositis (sIBM) is the most common acquired muscle disease in elderly individuals, particularly men. Its prevalence varies among ethnic groups but is estimated at 35 per one million people over 50. Genetic as well as environmental factors and autoimmune processes might both have a role in its pathogenesis. Unlike other inflammatory myopathies, sIBM causes very slowly progressive muscular weakness and atrophy, having a distinctive pattern of muscle involvement and different forms of clinical presentation. In some cases a primary autoimmune disease coexists. Diagnosis is suspected on clinical grounds and is established by typical muscle pathology. As a rule sIBM is refractory to conventional forms of immunotherapy.

© 2014 Elsevier B.V. All rights reserved.

Contents

| | |
|--------------------------------------|-----|
| 1. Introduction | 363 |
| 2. Epidemiology | 363 |
| 3. History | 364 |
| 4. Pathogenesis | 364 |
| 5. Clinical manifestations | 364 |
| 6. Differential diagnosis | 364 |
| 7. Pathological features | 364 |
| 8. Biochemical features | 364 |
| 9. Serological features | 364 |
| 10. Associated disorders | 365 |
| 11. Diagnostic criteria | 365 |
| 12. Prognosis | 365 |
| 13. Therapy | 365 |
| References | 365 |

1. Introduction

Sporadic inclusion body myositis (sIBM) is a progressive degenerative inflammatory disorder in skeletal muscle of unknown etiology. In addition, is one of the three main subsets of inflammatory myopathies, the other two being polymyositis and dermatomyositis. Although all of these conditions include inflammation in the endomysium, muscle fiber

necrosis, elevation of serum muscle enzymes and varying degrees of muscle weakness, sIBM is often misdiagnosed as polymyositis. sIBM should be distinguished from hereditary inclusion body myopathies (hIBM) in which histologic and ultrastructural findings resemble those of sIBM with one clear exception: the absence of inflammation.

2. Epidemiology

The prevalence of sIBM is estimated at between 4.5 to 9.5 per one million rising to 35 per million for people over 50 years old. Recent studies have reported differences in prevalence with respect to geographical location, being 1.0 in Turkey [1], 4.7 in Netherlands [2], 9.8 in Japan [3] or 50 in Western Australia [4]. A number of discrepancies

* Corresponding author at: Internal Medicine Service, Hospital Clínic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. Tel./fax: + 34 93 2275539.

E-mail addresses: macatala@clinic.ub.es (M. Catalán), aselva@vhebron.net (A. Selva-O'Callaghan), jmgraub@clinic.ub.es (J.M. Grau).

suggest that these numbers underestimate the true prevalence of this myopathy. On the basis of clinical reports from reference centers worldwide, it seems that sIBM is the most common acquired myopathy in patients above 50 years, affecting men slightly more frequently than women [5,6].

3. History

In 1971 Yunis and Samaha coined the term IBM for the definition of a myopathy that clinically resembled a chronic polymyositis but was pathologically characterized by the presence of vacuoles containing cytoplasmic degradation products with fibrillary nuclear and cytoplasmic inclusions [7]. A few years previously some authors had reported clinical cases suggestive of IBM. Since then, large series of patients have been described.

4. Pathogenesis

Although the underlying cause of sIBM is unclear, it seems that at least three processes might occur in parallel: a primary immune process due to T-cell mediated cytotoxicity, a non-immune process characterized by vacuolization and intracellular accumulation of amyloid-related molecules probably due to MHC-class I-induced stress [6,8], and mitochondrial dysfunction.

Choi et al. [9] demonstrated the elevated expression of transglutaminases 1 and 2 in the vacuoles of sIBM, co-localizing with amyloid-related proteins. They suggest that these enzymes participate in the formation of insoluble amyloid deposits and may thereby contribute to progressive debilitating muscle disease. This topic has been explored by Selva-O'Callaghan et al. [10] with interesting results. Genetic factors are presumed to play a role in sIBM based on an association between sIBM and certain HLA genes, in particular HLA – DR3. This association is present in nearly 75% of the cases, but this figure may vary in different ethnic groups [6,11,12]. Many recent studies have shown parallelism between sIBM and Alzheimer's disease, focusing on similarities between brain and muscle cells of Alzheimer and sIBM, respectively. These similarities include cellular aging, oxidative and endoplasmic reticulum stresses, mitochondrial abnormalities, proteasome inhibition and multiprotein aggregates [13–15].

5. Clinical manifestations

sIBM causes weakness and atrophy of the distal and proximal muscles and involvement of the quadriceps and deep finger flexors are clues to early diagnosis. The pattern is sometimes asymmetric resembling a motor neuron disease. Neck flexors and extensors are frequently affected. Heat drop and camptocormia (selective atrophy and weakness of paraspinal muscles) may occur, even as a form of clinical presentation. Facial involvement is rare but can be observed in HIV-related cases. Dysphagia occurs in up to 60% of patients with sIBM and again may be the form of presentation in rare cases. Sensory function is normal as well as tendon reflexes, but they become diminished or absent as the atrophy of major muscles occurs. The clinical course is always chronic or very chronic, lasting for years after the onset of symptoms and the diagnosis of the disease. Disease progression is slow but steady resembling that of a muscular dystrophy.

6. Differential diagnosis

sIBM is often misdiagnosed as polymyositis or other diseases and is frequently only suspected retrospectively when a patient with presumed polymyositis does not respond to therapy. In a patient complaining of falls due to weakness at the knees and feet with atrophic thighs and without paresthesias or cramps the most plausible diagnosis is sIBM. Useful data regarding differential diagnoses are shown in Table 1.

Table 1

Differential diagnoses (prominent data for each condition).

| | |
|---|--|
| Motor neuron disease: | Hyperreflexia, cramps, fasciculations Typical EMG |
| Polymyositis: | Subacute (weeks to months) Proximal and symmetrical muscle weakness High CK levels |
| Vacuolar myopathies: (myofibrillar myopathies, hIBM) | Lack of inflammation, negative MHC HLA-class I |

7. Pathological features

The common findings in muscle biopsy are perivascular and endomysial inflammatory infiltrates of varying degrees, rimmed vacuoles in atrophic fibers (Fig. 1), the presence of partial cellular invasion by CD8 cells, frequent cytochrome oxidase (COX)-negative cells, β -amyloid and tau deposits and the upregulation of MHC class I antigens in healthy muscle cells. In addition abnormal mitochondrial changes such as ragged-red fibers are frequently observed. Some of these features can be observed in Fig. 1. Nuclear and/or cytoplasmic filamentous inclusions of 16–20 nm are seen in electron microscopy examination [16]. Recent studies suggest that abnormal accumulation of extranuclear TDP-43, a nucleic acid-binding protein, in sarcoplasm of IBM muscle cells may be toxic through its binding to RNA [17,18]. On some occasions an additional muscle biopsy must be performed if pathological changes are suggestive but not consistent.

8. Biochemical features

Creatine kinase (CK) serum levels are moderately elevated but can be normal. Unlike other inflammatory conditions acute phase reactants are normal in sIBM.

9. Serological features

Different autoantibodies can be detected in a percentage of sIBM patients. Antinuclear antibodies (20%), rheumatoid factor (13%), anti-cardiolipin antibodies (10%), antiRo antibodies (10%) are the most frequently reported. In 2011, an autoantibody to an approximately 43 kDa human muscle protein was identified in 52% of IBM samples, 0% of other autoimmune myopathy samples and 0% of normal samples [19,20]. In about 10% of the cases dysproteinemia can also be detected [21].




Fig. 1. Variability in fiber size with prominent connective tissue. Mononuclear cells in the endomysium as well as invading a healthy muscle cell can be observed. Rimmed vacuoles are present on at least two fibers. A typical ragged-red fiber is also observed in the center of the picture. HE on frozen muscle biopsy from an sIBM patient.

Download English Version:

<https://daneshyari.com/en/article/6114465>

Download Persian Version:

<https://daneshyari.com/article/6114465>

[Daneshyari.com](https://daneshyari.com)